Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.

Abstract: A non-volatile bistable nano-electromechanical switch is provided for use in memory devices and microprocessors. The switch employs carbon nanotubes as the actuation element. A method has been developed for fabricating nanoswitches having one single-walled carbon nanotube as the actuator. The actuation of two different states can be achieved using the same low voltage for each state.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.

Abstract: The refractive index of the at least one photonic structure having two separate photonic bands is modulated, so that light supplied to the at least one photonic structure and initially in one of the two photonic bands of the traveling along a forward direction in the at least one photonic structure is converted to light in a second one of the photonic bands, and light in the one photonic band traveling along a backward direction opposite to the forward direction in the at least one photonic structure is not converted and remains in the one photonic band, achieving non-reciprocity.

Abstract: A plurality of gaming terminals each having a terminal display on which a plurality of symbols are lined up, a plurality of upper displays forming a single common effect image display screen constituted by gaming terminal areas corresponding to the respective gaming terminals, and a center controller are included. The center controller determines whether a common game is being run when an independent special game is started, and produces an effect in the gaming terminal area corresponding to the gaming terminal, only when the common game is not being run.

Abstract: Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment.

Abstract: Devices and methods for storing and injecting a corneal tissue graft are disclosed herein. In one embodiment, an apparatus includes a tissue container and an adaptor configured to be coupled to the tissue container. The tissue container defines an interior region configured to receive a precut corneal tissue graft therein. The tissue container is also configured to be coupled to an injector assembly that can be used to move the corneal tissue graft out of the interior region of the tissue container and into an anterior chamber of a recipient's eye. The adaptor can be configured to prevent the tissue graft from migrating out of the tissue container and/or can be configured to be coupled to the injector assembly. The tissue graft can remain within the tissue container during storage, transport and during the implantation procedure until it is injected into the patient's eye.

Abstract: The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.

Abstract: A computer implemented method for magnetic resonance imaging is provided. A 3D Fourier Transform acquisition is performed with two phase encode directions, wherein phase code locations are chosen so that a total number of phase encodes is less than a Nyquist rate, and closest distances between phase encode locations takes on a multiplicity of values. Readout signals are received through a multi-channel array of a plurality of receivers. An autocalibrating parallel imaging interpolation is performed and a noise correlation is generated. The noise correlation is used to weight a data consistency term of a compressed sensing iterative reconstruction. An image is created from the autocalibration parallel imaging using the weighted data consistency term. The image is displayed.

Abstract: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.

Abstract: Methods of synthesizing ammonia borane are provided. The methods comprise reacting at least one amine borane with ammonia such that ammonia borane is produced. Ammonia borane has a chemical formula of NH3.BH3 and provides a good source of storage hydrogen making it useful in a variety of applications including a potential hydrogen source for fuel cells. The methods can further comprise separating the ammonia borane from the other products of the reaction. Exemplary methods can produce ammonia borane having purity greater than about 90 percent. In further examples, the methods can produce ammonia borane having purity greater than about 95 percent or greater than about 99 percent.

Abstract: A composition of matter, and method to make same, for a nano-based material including a nanocarbon support to which is attached an aliphatic amine. In particular, the composition of matter is an aliphatic amine-nanocarbon material that includes a nanocarbon (NC) support, such as C60, nano-graphite, graphene, nanocarbon ribbons, graphite intercalation compounds, graphite oxide, nano-coal, nanohorns, and combinations thereof, and further includes an aliphatic amine, such as polyethyleneimine (PEI).

Abstract: The present invention includes compositions and methods for treating disorders of the skin or mucosa resulting from cancer therapies comprising: identifying a patient receiving cancer treatment; and administering to said patient an effective dose of a treated organic/inorganic complex material with an organic dye molecule or derivative thereof, in a pharmaceutically acceptable carrier.

Abstract: Presented herein are novel protein biomarkers related to cancers with stromal components. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of diagnosis and/or prognosis of cancer. A new genetic model able to identify potential genetic suppressors and/or potential therapeutic agents for treating stromal cancers is also described. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the biomarkers and the genetic model system in clinical, diagnostic and therapeutic uses is also included.

Abstract: The present invention provides a site-specific pegylated arginase conjugate and method for producing thereof. The site-specific pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method for producing the arginase conjugate comprises genetically modifying the gene encoding an arginase so that the PEG moiety can be attached to the enzyme at a predetermined, specific intended sites. This is achieved by removing the PEG-attaching amino acid residue(s) at undesirable site(s) while keeping or adding cysteine(s) at the desirable site(s) of the enzyme. Two exemplary embodiments of the pegylated arginase conjugate are directed to human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys45 of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys161 of the enzyme.

Abstract: A disclosed method includes extracting a region from each of plural cross sections in a volume data representing a solid to be rendered, based on data of brightness values of texels for each of the plurality of cross sections, wherein the plural cross sections are perpendicular to an axis set for the volume data; deleting any one of two adjacent cross sections among the plural cross sections based on a correlation between a region extracted for one cross section of the two adjacent cross sections and a region extracted for the other cross section of the two adjacent cross sections; and rendering the solid by using data of the cross sections after the deleting.

Abstract: This electric power fuse has a fuse element that is formed continuously and integrally by a plurality of heat dissipating parts formed from a conductive film by the conductive film being formed on a ceramic substrate and a plurality of isolating parts. The conductive film is constituted of printed layers formed by printing one or more times on the surface of the ceramic substrate, and the number of laminations of printed layers formed in the heat dissipating parts is greater than or equal to the number of laminations of the printed layers constituting the isolating parts.

Abstract: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.

Abstract: Novel organic compounds containing a twisted aryl group are provided. In particular, the compounds provided contain a 2-phenylpyridine ligand having a twisted aryl group on the pyridine portion of the ligand. The compounds may be used in organic light emitting devices, particularly as emitting dopants. Devices comprising the compounds containing twisted aryl may demonstrate improved color, efficiency, stability and manufacturing. Additionally, methods are provided for making homoleptic Ir (III) compounds which may contain a twisted aryl.